Trump FIRES Controversial FDA Head After One Year!

FDA building sign with blue sky background.

President Trump has reportedly signed off on firing his own Food and Drug Administration (FDA) commissioner after just over a year on the job — a chaotic tenure marked by internal dysfunction, clashes with the White House, and criticism from both sides of the political aisle.

Story Snapshot

Trump reportedly approved a plan to dismiss FDA Commissioner Marty Makary, according to multiple outlets citing White House sources familiar with the matter.
Makary clashed with the White House and the Department of Health and Human Services (HHS), with officials reportedly viewing him as a “rogue agent” acting independently.
Trump expressed direct frustration to Makary over the FDA’s refusal to review Moderna’s investigational mRNA-based flu vaccine.
Antiabortion groups criticized Makary for approving a generic version of the abortion drug mifepristone, while pharmaceutical companies blasted him for abrupt regulatory reversals.

Reports Say Trump Signed Off on Makary’s Removal

Multiple major outlets, including the Wall Street Journal and NBC News, report that President Trump approved a plan to dismiss FDA Commissioner Marty Makary. The reports, which cite people familiar with the matter, describe mounting frustration inside the White House over Makary’s handling of key regulatory decisions. No official White House statement has confirmed the move, and Trump himself told reporters he knew “nothing about it” — though anonymous sourcing from several outlets paints a different picture.

The uncertainty surrounding the reports is worth noting. All sourcing remains anonymous, with no named witnesses or official documents released. Both NBC News and BioSpace explicitly stated that Trump’s plan “is not final and could change.” Still, the volume and consistency of reporting across the Wall Street Journal, NBC, Politico, and STAT News suggests the frustration inside the administration is real, even if the final outcome remains unsettled.

A Tenure Plagued by Conflict on All Sides

Makary’s roughly 14-month tenure at the FDA was defined by controversy from multiple directions. Internally, he relied on a small inner circle and repeatedly clashed with both HHS and White House officials, who reportedly came to view him as a “rogue agent” operating outside the administration’s direction. That kind of independent posture is a serious problem in an executive branch where alignment with the president’s agenda is expected — and under Trump, it is non-negotiable.

Pharmaceutical companies also grew frustrated with Makary, criticizing him for what they described as costly regulatory “U-turns” — situations where the FDA initially signaled approval for drug development pathways, only to abruptly reverse course. Those reversals created expensive setbacks for drug developers and raised questions about the consistency and predictability of FDA decision-making under his leadership.

Vaccine Disputes and Mifepristone Backlash Compounded Pressure

The breaking point with the White House reportedly came over vaccine policy. According to Politico, Trump called Makary to the White House and directly expressed frustration over the FDA’s refusal to review Moderna’s investigational mRNA-based flu vaccine. Makary had also pushed for large placebo-controlled trials of COVID-19 vaccines in lower-risk groups — a position aligned with the Make America Healthy Again (MAHA) movement but one that created friction across the regulatory landscape.

Trump weighs firing Dr. Marty Makary as FDA chief – NBC News https://t.co/q8eZsOtV9i

— Arnaud Mercier – #Entrepreneur #Versailles (@arnaudmercier) May 10, 2026

Conservative antiabortion groups added to the pressure from another direction. Makary faced sharp backlash for declining to restrict access to mifepristone and for approving a generic version of the abortion drug — decisions that angered a key part of Trump’s base. Taken together, the criticism from the White House, the pharmaceutical industry, and social conservatives left Makary with few allies and a shrinking base of support inside an administration that demands loyalty and results.

What This Means for Federal Health Agency Leadership

If Makary is removed, his departure would add to an already significant list of vacancies across federal health agencies. As of this reporting, there is no permanent director at the Centers for Disease Control and Prevention (CDC) and no confirmed Surgeon General, with Senate confirmation backlogs slowing replacements. The FDA plays a critical role in drug approvals, vaccine oversight, and food safety — and extended leadership uncertainty at the agency carries real consequences for both public health and the regulatory environment that affects millions of Americans.